CXCR4-overexpressing neoplastic diseases encompass hematological malignancies, breast cancer, ovarian cancer, among others, as well as non-neoplastic lesions primarily comprising primary aldosteronism, aldosterone-producing adenomas, myocardial infarction, and inflammatory diseases.
Conditions
Interventions
Gold Standard:For neoplastic diseases, the diagnostic standard was pathology. For non-neoplastic conditions: primary aldosteronism was confirmed by adrenal venous sampling postoperative immunohistopat
myocardial infarction by coronary angiography
inflammatory diseases by pathology
Index test:18F/68Ga-SMIC-1501W PET imaging
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
19 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Malignant Tumors: (1) Age >= 18 years. (2)Voluntarily signed informed consent. (3) Patients with a confirmed diagnosis of primary malignant tumor, established via pathological biopsy, diagnostic treatment, or clinical follow-up. 2. Primary Aldosteronism: Diagnostic Criteria: Patients who meet the diagnostic criteria outlined in the Chinese Expert Consensus on the Diagnosis and Treatment of Primary Aldosteronism (2024 Edition). Inclusion Criteria: (1) Age >= 18 years. (2) Voluntarily signed informed consent. (3)Diagnosis of primary aldosteronism confirmed by an experienced endocrinologist. 3. Myocardial Infarction Diagnostic Criteria: Patients diagnosed with acute myocardial infarction (AMI) according to the *2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Acute Coronary Syndromes*. Inclusion Criteria: (1) Age >= 18 years. (2) Voluntarily provided informed consent. (3) Newly diagnosed AMI confirmed by an experienced cardiologist. Successful percutaneous coronary intervention (PCI). 4. Inflammatory Diseases Inclusion Criteria: (1) Age >= 18 years. (2) Voluntarily signed informed consent. (3) Confirmed diagnosis of an inflammatory disease by an experienced specialist, based on a combination of endoscopic findings, serological testing, and pathological results.
Exclusion criteria
Exclusion criteria: 1.Malignant Tumors: Hematologic malignancies, breast cancer, ovarian cancer, etc. Exclusion Criteria: (1) Pregnancy or lactation. (2) Severe cardiac, hepatic, or renal failure (eGFR < 30 mL/min). (3) Contraindications to PET/CT examination. (4) Inability to establish a definitive diagnosis of malignant tumor. 2.Primary Aldosteronism: Exclusion Criteria: (1) Pregnancy or lactation. (2) Severe cardiac, hepatic, or renal failure (eGFR < 30 mL/min). (3) Contraindications to PET/CT examination. (4) Prior adrenal surgery. (5) Coexisting Cushing's syndrome or other malignant tumors. 3.Myocardial Infarction: Exclusion Criteria: (1) Pregnancy or lactation. (2) Severe cardiac, hepatic, or renal failure (eGFR < 30 mL/min). (3) Contraindications to PET/CT examination.(4) History of prior myocardial infarction or other significant heart disease. (5) Concurrent autoimmune or infectious diseases. 4.Inflammatory Diseases: Exclusion Criteria: (1) Pregnancy or lactation. (2) Severe cardiac, hepatic, or renal failure (eGFR < 30 mL/min). (3) Contraindications to PET/CT examination. (4) Coexisting malignant tumors or active infectious diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| specificity;Sensitivity;accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation coefficient between SUVmax and CXCR4 expression level;Quality control and radiochemical purity of the radiopharmaceuticals;Negative Predictive Value;Positive Predictive Value; | — |
Countries
China
Contacts
Public ContactChao Ma
Shanghai Tenth People's Hospital
Outcome results
None listed